查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153436

2026-2034年轉移性乳癌治療全球市場規模、佔有率、趨勢和成長分析報告

Global Metastatic Breast Cancer Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球轉移性乳癌治療市場預計將從2025年的244.4億美元成長至2034年的671.8億美元，2026年至2034年的複合年成長率（CAGR）為11.89%。這個市場擴張的原因在於乳癌發生率的上升以及對先進療法需求的成長。轉移性乳癌的治療需要標靶治療、免疫療法和荷爾蒙療法等特殊療法。醫學研究的進步和診斷技術的改進正在推動早期發現和更好的治療效果。

關鍵成長要素包括創新藥物的研發和個人化醫療方法。製藥公司正大力投資研發，以開發療效更佳、副作用更少的療法。人們對癌症篩檢和早期診斷意識的提高也促進了市場成長。此外，醫療基礎設施的改善和治療可近性的提高也帶來了更好的患者療效。

未來，隨著新療法和精準醫療的引入，市場預計將持續成長。人工智慧（AI）在藥物研發和治療方案製定中的應用將進一步推動該領域的發展。在新興市場，隨著醫療保健體系的完善，預計需求將會增加。持續的研究和創新對於應對轉移性乳癌帶來的挑戰仍然至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球轉移性乳癌治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 荷爾蒙療法
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第5章 全球轉移性乳癌治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 全身性治療
  • 局部治療

第6章 全球轉移性乳癌治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

第7章 全球轉移性乳癌治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Roche
    • AstraZeneca
    • Novartis
    • Pfizer
    • Eli Lilly
    • Merck & Co
    • Bristol Myers Squibb
    • Gilead Sciences
    • Daiichi Sankyo
    • Seagen
    • AbbVie
    • Amgen
    • Genentech
    • BeiGene
    • Menarini Group
    • Radius Health
    • Puma Biotechnology
    • MacroGenics
    • Immunomedics
    • Stemline Therapeutics
簡介目錄
Product Code: VMR11216767

The global metastatic breast cancer treatment market size is expected to reach USD 67.18 Billion in 2034 from USD 24.44 Billion in 2025, growing at a CAGR of 11.89% during 2026-2034.This market is expanding due to the increasing prevalence of breast cancer and the growing demand for advanced treatment options. Metastatic breast cancer requires specialized therapies, including targeted treatments, immunotherapy, and hormone therapy. Advances in medical research and improved diagnostic techniques are contributing to early detection and better treatment outcomes.

Key drivers include the development of innovative drugs and personalized medicine approaches. Pharmaceutical companies are investing heavily in research to create more effective therapies with fewer side effects. Increasing awareness about cancer screening and early diagnosis is also supporting market growth. Additionally, improvements in healthcare infrastructure and access to treatment are enhancing patient outcomes.

In the future, the market is expected to grow with the introduction of novel therapies and precision medicine. The integration of artificial intelligence in drug discovery and treatment planning will further advance the field. Emerging markets are likely to see increased demand due to improving healthcare systems. Continuous research and innovation will remain critical in addressing the challenges associated with metastatic breast cancer.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

By Treatment Type

  • Systemic Therapy
  • Local Therapy

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

COMPANIES PROFILED

  • Roche, AstraZeneca, Novartis, Pfizer, Eli Lilly, Merck & Co., Bristol Myers Squibb, Gilead Sciences, Daiichi Sankyo, Seagen, AbbVie, Amgen, Genentech, BeiGene, Menarini Group, Radius Health, Puma Biotechnology, MacroGenics, Immunomedics, Stemline Therapeutics

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Therapy Type
  • 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment Type
  • 5.2. Systemic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Local Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL METASTATIC BREAST CANCER TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Therapy Type
    • 7.2.2 By Treatment Type
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Therapy Type
    • 7.3.2 By Treatment Type
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Therapy Type
    • 7.4.2 By Treatment Type
    • 7.4.3 By End-user
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Therapy Type
    • 7.5.2 By Treatment Type
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Therapy Type
    • 7.6.2 By Treatment Type
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL METASTATIC BREAST CANCER TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Roche
    • 9.2.2 AstraZeneca
    • 9.2.3 Novartis
    • 9.2.4 Pfizer
    • 9.2.5 Eli Lilly
    • 9.2.6 Merck & Co
    • 9.2.7 Bristol Myers Squibb
    • 9.2.8 Gilead Sciences
    • 9.2.9 Daiichi Sankyo
    • 9.2.10 Seagen
    • 9.2.11 AbbVie
    • 9.2.12 Amgen
    • 9.2.13 Genentech
    • 9.2.14 BeiGene
    • 9.2.15 Menarini Group
    • 9.2.16 Radius Health
    • 9.2.17 Puma Biotechnology
    • 9.2.18 MacroGenics
    • 9.2.19 Immunomedics
    • 9.2.20 Stemline Therapeutics